Aveanna’s latest earnings move and analyst reaction
Aveanna Healthcare Holdings (AVAH) is back on investors’ radar after its fourth quarter update, where management reported 20.2% annual revenue growth and a 74.8% increase in Adjusted EBITDA, followed by Barclays revisiting its view on the stock.
See our latest analysis for Aveanna Healthcare Holdings.
At a latest share price of $6.38, Aveanna’s short term share price performance has been weak, with a 30 day share price return of an 11.8% decline and a 90 day share price return of a 22.4% decline. However, its 1 year total shareholder return of 26.8% and very large 3 year total shareholder return suggest that longer term momentum has been much stronger.
If Aveanna’s update has you rethinking where growth in healthcare could come from next, it may be worth scanning 36 healthcare AI stocks
With Aveanna trading at $6.38 and a reported intrinsic discount alongside a sizeable gap to analysts’ price target, investors now have to ask: is there genuine value here, or has the market already priced in future growth?
Most Popular Narrative: 37.8% Undervalued
At a last close of $6.38 versus a narrative fair value of $10.25, the widely followed view is that Aveanna’s current price leaves a meaningful valuation gap open.
Accelerating adoption of home-based healthcare and increasing patient preference for in-home care are driving strong and sustained demand for Aveanna's services, which management repeatedly noted remains robust and outstrips the company's current capacity, supporting the potential for significant future revenue growth as the company hires and retains more caregivers.
Curious what turns that demand story into a higher fair value estimate? The narrative focuses on how revenue, margins and future earnings could reshape Aveanna’s earnings power.
Result: Fair Value of $10.25 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to weigh risks such as heavy reliance on Medicaid and Medicare reimbursement and the impact of US$1.47b in variable rate debt on flexibility.
Find out about the key risks to this Aveanna Healthcare Holdings narrative.
Next Steps
Seeing both optimism and concern in the story so far, it makes sense to review the numbers yourself and move quickly to form your own judgment using 3 key rewards and 4 important warning signs.
Looking for more investment ideas?
If you stop with just one stock, you risk missing other opportunities that might fit your goals even better. Broaden your watchlist before the market moves.
- Target potential standouts by scanning a screener containing 25 high quality undiscovered gems that focuses on quality businesses the market may not be paying close attention to yet.
- Strengthen your core holdings with a solid balance sheet and fundamentals stocks screener (40 results) that highlights companies prioritising financial resilience and cleaner balance sheets.
- Prioritise staying power by reviewing a 68 resilient stocks with low risk scores that filters for stocks with lower risk scores and steadier profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com